CL2022000666A1 - Compuesto de piridona fusionada y método de preparación del mismo y uso del mismo - Google Patents

Compuesto de piridona fusionada y método de preparación del mismo y uso del mismo

Info

Publication number
CL2022000666A1
CL2022000666A1 CL2022000666A CL2022000666A CL2022000666A1 CL 2022000666 A1 CL2022000666 A1 CL 2022000666A1 CL 2022000666 A CL2022000666 A CL 2022000666A CL 2022000666 A CL2022000666 A CL 2022000666A CL 2022000666 A1 CL2022000666 A1 CL 2022000666A1
Authority
CL
Chile
Prior art keywords
preparation
compound
pyridone compound
fused
fused pyridone
Prior art date
Application number
CL2022000666A
Other languages
English (en)
Inventor
Shuchun Guo
Jun Fan
Yang Liu
Fang Bao
Jianbiao Peng
Haibing Guo
Original Assignee
Shanghai Jemincare Pharmaceuticals Co Ltd
Jiangxi Jemincare Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jemincare Pharmaceuticals Co Ltd, Jiangxi Jemincare Group Co Ltd filed Critical Shanghai Jemincare Pharmaceuticals Co Ltd
Publication of CL2022000666A1 publication Critical patent/CL2022000666A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

En la presente invención se describe un compuesto de piridona fusionada, y un método de preparación para este y un uso de este. Específicamente, la presente invención describe un compuesto de la fórmula (I-B), un isómero óptico del mismo y una sal farmacéuticamente aceptable del mismo, y el uso del compuesto como inhibidor de KRAS.
CL2022000666A 2019-09-20 2022-03-18 Compuesto de piridona fusionada y método de preparación del mismo y uso del mismo CL2022000666A1 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201910892032 2019-09-20
CN201911129688 2019-11-18
CN201911157939 2019-11-22
CN202010054188 2020-01-17
CN202010102546 2020-02-19
CN202010230303 2020-03-27
CN202010306926 2020-04-17
CN202010367694 2020-04-30
CN202010967317 2020-09-15

Publications (1)

Publication Number Publication Date
CL2022000666A1 true CL2022000666A1 (es) 2022-10-14

Family

ID=74883935

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000666A CL2022000666A1 (es) 2019-09-20 2022-03-18 Compuesto de piridona fusionada y método de preparación del mismo y uso del mismo

Country Status (14)

Country Link
US (1) US20220389029A1 (es)
EP (1) EP4043464A4 (es)
JP (1) JP2022549171A (es)
KR (1) KR20220086573A (es)
CN (2) CN114728968A (es)
AU (1) AU2020350745A1 (es)
BR (1) BR112022005193A2 (es)
CA (1) CA3155066A1 (es)
CL (1) CL2022000666A1 (es)
CO (1) CO2022004686A2 (es)
IL (1) IL291467A (es)
MX (1) MX2022003401A (es)
TW (1) TWI761961B (es)
WO (1) WO2021052499A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
KR20220091480A (ko) 2019-09-24 2022-06-30 미라티 테라퓨틱스, 인크. 병용 요법
CA3158793A1 (en) 2019-10-28 2021-05-06 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
US20230084095A1 (en) * 2019-10-30 2023-03-16 Genfleet Therapeutics (Shanghai) Inc. Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof
BR112022012106A2 (pt) 2019-12-20 2022-09-20 Mirati Therapeutics Inc Inibidores de sos1
AU2021248363B2 (en) * 2020-04-03 2024-02-15 Medshine Discovery Inc. Octahydropyrazinodiazanaphthyridine dione compounds
WO2022037630A1 (zh) * 2020-08-21 2022-02-24 浙江海正药业股份有限公司 四环类衍生物、其制备方法及其医药上的用途
CN116670136A (zh) * 2020-12-31 2023-08-29 正大天晴药业集团股份有限公司 四环类化合物及其医药用途
WO2022199669A1 (zh) * 2021-03-25 2022-09-29 上海济煜医药科技有限公司 稠合吡啶酮类化合物盐型、晶型及其应用
CN115124533A (zh) * 2021-03-26 2022-09-30 浙江海正药业股份有限公司 四环类衍生物、其制备方法和其医药上的用途
WO2022198904A1 (zh) * 2021-03-26 2022-09-29 浙江海正药业股份有限公司 一种kras抑制剂关键中间体及其制备方法
WO2022206723A1 (zh) * 2021-03-30 2022-10-06 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
WO2022223037A1 (zh) * 2021-04-22 2022-10-27 劲方医药科技(上海)有限公司 Kras抑制剂的盐或多晶型物
WO2023001141A1 (en) * 2021-07-23 2023-01-26 Shanghai Zion Pharma Co. Limited Kras g12d inhibitors and uses thereof
CN117222654A (zh) * 2021-09-06 2023-12-12 苏州赞荣医药科技有限公司 Kras g12c抑制剂和其用途
WO2023116895A1 (zh) * 2021-12-24 2023-06-29 劲方医药科技(上海)有限公司 Kras抑制剂的多晶型物及其制备方法和用途
CN116327956A (zh) * 2022-04-01 2023-06-27 劲方医药科技(上海)有限公司 药物组合物、其用途及癌症的治疗方法
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016008016B8 (pt) * 2013-10-10 2023-09-26 Araxes Pharma Llc Compostos inibidores de kras g12c, composição farmacêutica compreendendo ditos compostos, métodos para regular a atividade e para preparar uma proteína mutante kras, hras ou nras g12c, método para inibir a proliferação de uma população de células e usos terapêuticos dos ditos compostos
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
EP3280708B1 (en) * 2015-04-10 2021-09-01 Araxes Pharma LLC Substituted quinazoline compounds and methods of use thereof
MX2017013275A (es) * 2015-04-15 2018-01-26 Araxes Pharma Llc Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos.
WO2017100546A1 (en) * 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2018142365A1 (en) * 2017-02-03 2018-08-09 The University Of North Carolina At Chapel Hill Inhibitors of microbial beta-glucuronidase enzymes and uses thereof
EP3621968A1 (en) * 2017-05-11 2020-03-18 Astrazeneca AB Heteroaryl compounds that inhibit g12c mutant ras proteins
JOP20190272A1 (ar) * 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
WO2019110751A1 (en) * 2017-12-08 2019-06-13 Astrazeneca Ab Tetracyclic compounds as inhibitors of g12c mutant ras protein, for use as anti-cancer agents
US11453667B2 (en) * 2018-01-19 2022-09-27 Medshine Discovery Inc. Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor
JP7266043B2 (ja) * 2018-05-04 2023-04-27 アムジエン・インコーポレーテツド ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法
WO2020156285A1 (zh) * 2019-01-29 2020-08-06 博瑞生物医药（苏州）股份有限公司 一种苯并吡啶酮杂环化合物及其用途
CN113396147B (zh) * 2019-05-31 2024-06-18 上海翰森生物医药科技有限公司 芳香杂环类衍生物调节剂、其制备方法和应用
CN112300194B (zh) * 2019-07-30 2022-01-14 上海凌达生物医药有限公司 一类稠环吡啶酮类化合物、制备方法和用途
US20230084095A1 (en) * 2019-10-30 2023-03-16 Genfleet Therapeutics (Shanghai) Inc. Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof

Also Published As

Publication number Publication date
US20220389029A1 (en) 2022-12-08
TWI761961B (zh) 2022-04-21
EP4043464A1 (en) 2022-08-17
BR112022005193A2 (pt) 2022-08-16
TW202126654A (zh) 2021-07-16
IL291467A (en) 2022-05-01
KR20220086573A (ko) 2022-06-23
CN114728968A (zh) 2022-07-08
CN116947885A (zh) 2023-10-27
MX2022003401A (es) 2022-07-13
EP4043464A4 (en) 2023-10-04
AU2020350745A1 (en) 2022-04-07
JP2022549171A (ja) 2022-11-24
CA3155066A1 (en) 2021-03-25
CO2022004686A2 (es) 2022-07-08
WO2021052499A1 (zh) 2021-03-25

Similar Documents

Publication Publication Date Title
CL2022000666A1 (es) Compuesto de piridona fusionada y método de preparación del mismo y uso del mismo
MX2022001421A (es) Compuesto tetracíclico, método de preparación y uso del mismo.
ECSP17054980A (es) Inhibidores selectivos de bace1
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
CL2019001694A1 (es) Compuestos de pirazolopirimidina y métodos de uso de los mismos.
CO2020004301A2 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
UY35362A (es) Compuestos terapéuticos
CL2017000820A1 (es) Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos
SV2016005351A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
EA202193015A1 (ru) Ингибиторы cdk
CO2022008171A2 (es) Derivado tricíclico de dihidroimidazopirimidona, método de preparación del mismo, composición farmacéutica y uso del mismo
CL2018001067A1 (es) Compuesto piranodipiridínico.
DK3840832T3 (da) Imidazo[1,2-b]pyridaziner som trk-inhibitorer
UY36124A (es) Derivados de carboxamida
CO2019005165A2 (es) Compuesto de piridona como inhibidor de c-met
EA202191192A1 (ru) Кристаллические соли ингибитора плазменного калликреина
AR106475A1 (es) Derivados de piridina o de pirimidina
ECSP19013196A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
CO2021004873A2 (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
CO2020012574A2 (es) Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida
AR104241A1 (es) Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
UY36084A (es) Activadores de herg policíclicos